| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2024 ( Subtotal = $290,895 ) |
| | 2024 | 2024 | INTERNATIONAL AIDS VACCINE INITIATIVE INC. | 125 BROAD ST FL 9 | NEW YORK | NY | 10004-2743 | NEW YORK | USA | R61AI169132 | Development of Novel mRNA Vaccines Against Mycobacterium tuberculosis | 001 | 3 | NIH | 4/16/2024 | $224,384 |
| | 2024 | 2024 | INTERNATIONAL AIDS VACCINE INITIATIVE INC. | 125 BROAD ST FL 9 | NEW YORK | NY | 10004-2743 | NEW YORK | USA | R61AI169132 | Development of Novel mRNA Vaccines Against Mycobacterium tuberculosis | 002 | 3 | NIH | 8/12/2024 | $0 |
| | 2024 | 2024 | INTERNATIONAL AIDS VACCINE INITIATIVE INC. | 125 BROAD ST FL 9 | NEW YORK | NY | 10004-2743 | NEW YORK | USA | R61AI169132 | Development of Novel mRNA Vaccines Against Mycobacterium tuberculosis | 002 | 3 | NIH | 8/12/2024 | $0 |
| | 2024 | 2024 | INTERNATIONAL AIDS VACCINE INITIATIVE INC. | 125 BROAD ST FL 9 | NEW YORK | NY | 10004-2743 | NEW YORK | USA | R61AI169132 | Development of Novel mRNA Vaccines Against Mycobacterium tuberculosis | 001 | 3 | NIH | 4/16/2024 | $224,384 |
| | 2024 | 2023 | INTERNATIONAL AIDS VACCINE INITIATIVE INC | 125 BROAD ST | NEW YORK | NY | 10004-2743 | NEW YORK | USA | R61AI169132 | Development of Novel mRNA Vaccines Against Mycobacterium tuberculosis | 000 | 2 | NIH | 11/15/2023 | $0 |
| | 2024 | 2023 | INTERNATIONAL AIDS VACCINE INITIATIVE INC | 125 BROAD ST | NEW YORK | NY | 10004-2743 | NEW YORK | USA | R61AI169132 | Development of Novel mRNA Vaccines Against Mycobacterium tuberculosis | 000 | 2 | NIH | 11/15/2023 | $0 |
| | 2024 | 2019 | INTERNATIONAL AIDS VACCINE INITIATIVE INC. | 125 BROAD ST FL 9 | NEW YORK | NY | 10004-2743 | NEW YORK | USA | U01AI131861 | MTBVAC Phase 1b/2a Randomized, Double-blind, Active-controlled, Safety, Immunogenicity, and Dose-escalation Study in Adults with and without Latent Tuberculosis Infection in South Africa | 001 | 4 | NIH | 4/17/2024 | -$114,061 |
| | 2024 | 2018 | INTERNATIONAL AIDS VACCINE INITIATIVE INC. | 125 BROAD ST FL 9 | NEW YORK | NY | 10004-2743 | NEW YORK | USA | U01AI131861 | MTBVAC Phase 1b/2a Randomized, Double-blind, Active-controlled, Safety, Immunogenicity, and Dose-escalation Study in Adults with and without Latent Tuberculosis Infection in South Africa | 000 | 3 | NIH | 10/1/2023 | -$43,812 |
|
| Issue Date FY: 2023 ( Subtotal = $418,976 ) |
| | 2023 | 2023 | INTERNATIONAL AIDS VACCINE INITIATIVE INC | 125 BROAD ST | NEW YORK | NY | 10004-2743 | NEW YORK | USA | R61AI169132 | Development of Novel mRNA Vaccines Against Mycobacterium tuberculosis | 001 | 2 | NIH | 6/5/2023 | $211,133 |
| | 2023 | 2023 | INTERNATIONAL AIDS VACCINE INITIATIVE INC | 125 BROAD ST | NEW YORK | NY | 10004-2743 | NEW YORK | USA | R61AI169132 | Development of Novel mRNA Vaccines Against Mycobacterium tuberculosis | 001 | 2 | NIH | 6/5/2023 | $211,133 |
| | 2023 | 2022 | INTERNATIONAL AIDS VACCINE INITIATIVE INC | 125 BROAD ST | NEW YORK | NY | 10004-2743 | NEW YORK | USA | R61AI169132 | Development of Novel mRNA Vaccines Against Mycobacterium tuberculosis | 000 | 1 | NIH | 4/27/2023 | $0 |
| | 2023 | 2022 | INTERNATIONAL AIDS VACCINE INITIATIVE INC | 125 BROAD ST | NEW YORK | NY | 10004-2743 | NEW YORK | USA | R61AI169132 | Development of Novel mRNA Vaccines Against Mycobacterium tuberculosis | 000 | 1 | NIH | 4/27/2023 | $0 |
| | 2023 | 2021 | INTERNATIONAL AIDS VACCINE INITIATIVE INC | 125 BROAD ST | NEW YORK | NY | 10004-2743 | NEW YORK | USA | R13AI157206 | 6th Global Forum on TB Vaccines | 000 | 1 | NIH | 5/25/2023 | $0 |
| | 2023 | 2020 | INTERNATIONAL AIDS VACCINE INITIATIVE INC | 125 BROAD ST | NEW YORK | NY | 10004-2743 | NEW YORK | USA | P01AI124337 | Pushing the envelope: Optimizing vaccine display of flexibly linked HIV Env trimer immunogens | 000 | 5 | NIH | 7/26/2023 | -$3,290 |
|
| Issue Date FY: 2022 ( Subtotal = $465,219 ) |
| | 2022 | 2022 | INTERNATIONAL AIDS VACCINE INITATIVE INC. | 125 BROAD ST FL 9TH | NEW YORK | NY | 10004-2743 | NEW YORK | USA | R61AI169132 | Development of Novel mRNA Vaccines Against Mycobacterium tuberculosis | 000 | 1 | NIH | 5/20/2022 | $465,219 |
| | 2022 | 2022 | INTERNATIONAL AIDS VACCINE INITATIVE INC. | 125 BROAD ST FL 9TH | NEW YORK | NY | 10004-2743 | NEW YORK | USA | R61AI169132 | Development of Novel mRNA Vaccines Against Mycobacterium tuberculosis | 001 | 1 | NIH | 5/25/2022 | $232,609 |
| | 2022 | 2022 | INTERNATIONAL AIDS VACCINE INITATIVE INC. | 125 BROAD ST FL 9TH | NEW YORK | NY | 10004-2743 | NEW YORK | USA | R61AI169132 | Development of Novel mRNA Vaccines Against Mycobacterium tuberculosis | 001 | 1 | NIH | 5/25/2022 | -$232,609 |
| | 2022 | 2019 | INTERNATIONAL AIDS VACCINE INITATIVE INC. | 125 BROAD ST FL 9TH | NEW YORK | NY | 10004-2743 | NEW YORK | USA | U01AI131861 | MTBVAC Phase 1b/2a Randomized, Double-blind, Active-controlled, Safety, Immunogenicity, and Dose-escalation Study in Adults with and without Latent Tuberculosis Infection in South Africa | 002 | 4 | NIH | 8/1/2022 | $0 |
| | 2022 | 2019 | INTERNATIONAL AIDS VACCINE INITATIVE INC. | 125 BROAD ST FL 9TH | NEW YORK | NY | 10004-2743 | NEW YORK | USA | U01AI131861 | MTBVAC Phase 1b/2a Randomized, Double-blind, Active-controlled, Safety, Immunogenicity, and Dose-escalation Study in Adults with and without Latent Tuberculosis Infection in South Africa | 000 | 4 | NIH | 5/23/2022 | $0 |
| | 2022 | 2018 | INTERNATIONAL AIDS VACCINE INITATIVE INC. | 125 BROAD ST FL 9TH | NEW YORK | NY | 10004-2743 | NEW YORK | USA | U01AI131861 | MTBVAC Phase 1b/2a Randomized, Double-blind, Active-controlled, Safety, Immunogenicity, and Dose-escalation Study in Adults with and without Latent Tuberculosis Infection in South Africa | 001 | 3 | NIH | 5/23/2022 | $0 |
|
| Issue Date FY: 2021 ( Subtotal = $6,500 ) |
| | 2021 | 2021 | INTERNATIONAL AIDS VACCINE INITATIVE INC. | 125 BROAD ST FL 9TH | NEW YORK | NY | 10004-2743 | NEW YORK | USA | R13AI157206 | 6th Global Forum on TB Vaccines | 000 | 1 | NIH | 4/15/2021 | $6,500 |
| | 2021 | 2019 | INTERNATIONAL AIDS VACCINE INITATIVE INC. | 125 BROAD ST FL 9TH | NEW YORK | NY | 10004-2743 | NEW YORK | USA | U01AI131861 | MTBVAC Phase 1b/2a Randomized, Double-blind, Active-controlled, Safety, Immunogenicity, and Dose-escalation Study in Adults with and without Latent Tuberculosis Infection in South Africa | 000 | 4 | NIH | 9/16/2021 | $0 |
|
| Issue Date FY: 2020 ( Subtotal = $2,249,057 ) |
| | 2020 | 2020 | INTERNATIONAL AIDS VACCINE INITATIVE INC. | 125 BROAD ST FL 9TH | NEW YORK | NY | 10004-2743 | NEW YORK | USA | P01AI124337 | Pushing the envelope: Optimizing vaccine display of flexibly linked HIV Env trimer immunogens | 000 | 5 | NIH | 6/24/2020 | $2,249,057 |
| | 2020 | 2019 | INTERNATIONAL AIDS VACCINE INITATIVE INC. | 125 BROAD ST FL 9TH | NEW YORK | NY | 10004-2743 | NEW YORK | USA | U01AI131861 | MTBVAC Phase 1b/2a Randomized, Double-blind, Active-controlled, Safety, Immunogenicity, and Dose-escalation Study in Adults with and without Latent Tuberculosis Infection in South Africa | 000 | 4 | NIH | 7/21/2020 | $0 |
|
| Issue Date FY: 2019 ( Subtotal = $3,068,236 ) |
| | 2019 | 2019 | INTERNATIONAL AIDS VACCINE INITATIVE INC | 125 BROAD ST FL 9TH | NEW YORK | NY | 10004-2743 | NEW YORK | USA | P01AI124337 | Pushing the envelope: Optimizing vaccine display of flexibly linked HIV Env trimer immunogens | 000 | 4 | NIH | 7/2/2019 | $2,353,868 |
| | 2019 | 2019 | INTERNATIONAL AIDS VACCINE INITATIVE INC. | 125 BROAD ST FL 9TH | NEW YORK | NY | 10004-2743 | NEW YORK | USA | U01AI131861 | MTBVAC Phase 1b/2a Randomized, Double-blind, Active-controlled, Safety, Immunogenicity, and Dose-escalation Study in Adults with and without Latent Tuberculosis Infection in South Africa | 002 | 4 | NIH | 9/5/2019 | $131,886 |
| | 2019 | 2018 | INTERNATIONAL AIDS VACCINE INITATIVE INC | 125 BROAD ST FL 9TH | NEW YORK | NY | 10004-2743 | NEW YORK | USA | U01AI131861 | MTBVAC Phase 1b/2a Randomized, Double-blind, Active-controlled, Safety, Immunogenicity, and Dose-escalation Study in Adults with and without Latent Tuberculosis Infection in South Africa | 000 | 3 | NIH | 4/16/2019 | $372,482 |
| | 2019 | 2018 | INTERNATIONAL AIDS VACCINE INITATIVE INC. | 125 BROAD ST FL 9TH | NEW YORK | NY | 10004-2743 | NEW YORK | USA | U01AI131861 | MTBVAC Phase 1b/2a Randomized, Double-blind, Active-controlled, Safety, Immunogenicity, and Dose-escalation Study in Adults with and without Latent Tuberculosis Infection in South Africa | 004 | 3 | NIH | 9/5/2019 | $210,000 |
|
| Issue Date FY: 2018 ( Subtotal = $2,635,377 ) |
| | 2018 | 2018 | INTERNATIONAL AIDS VACCINE INITATIVE INC | 125 BROAD ST FL 9TH | NEW YORK | NY | 10004-2743 | NEW YORK | USA | P01AI124337 | Pushing the envelope: Optimizing vaccine display of flexibly linked HIV Env trimer immunogens | 000 | 3 | NIH | 6/22/2018 | $2,635,377 |
|
| Issue Date FY: 2017 ( Subtotal = $2,445,841 ) |
| | 2017 | 2017 | INTERNATIONAL AIDS VACCINE INITATIVE INC | 125 BROAD ST FL 9TH | NEW YORK | NY | 10004-2743 | NEW YORK | USA | P01AI124337 | Pushing the envelope: Optimizing vaccine display of flexibly linked HIV Env trimer immunogens | 000 | 2 | NIH | 8/7/2017 | $2,445,841 |
|
| Issue Date FY: 2016 ( Subtotal = $2,525,443 ) |
| | 2016 | 2016 | INTERNATIONAL AIDS VACCINE INITIATIVE | 110 WILLIAM STREET | NEW YORK | NY | 10038 | NEW YORK | USA | P01AI124337 | Pushing the envelope: Optimizing vaccine display of flexibly linked HIV Env trimer immunogens | 000 | 1 | NIH | 7/19/2016 | $2,434,199 |
| | 2016 | 2016 | INTERNATIONAL AIDS VACCINE INITIATIVE | 110 WILLIAM STREET | NEW YORK | NY | 10038 | NEW YORK | USA | P01AI124337 | Pushing the envelope: Optimizing vaccine display of flexibly linked HIV Env trimer immunogens | 001 | 1 | NIH | 8/12/2016 | $91,244 |
|
| Issue Date FY: 2015 ( Subtotal = $0 ) |
| | 2015 | 2014 | INTERNATIONAL AIDS VACCINE INITIATIVE | 110 WILLIAM STREET | NEW YORK | NY | 10038 | NEW YORK | USA | U19AI090970 | Interplay of B cells and HIV Leading to Broad Neutralizing Antibody Responses | 001 | 5 | NIH | 10/22/2014 | -$371,239 |
| | 2015 | 2014 | INTERNATIONAL AIDS VACCINE INITIATIVE | 110 WILLIAM STREET | NEW YORK | NY | 10038 | NEW YORK | USA | U19AI090970 | Interplay of B cells and HIV Leading to Broad Neutralizing Antibody Responses | 000 | 5 | NIH | 10/17/2014 | $371,239 |
|
| Issue Date FY: 2014 ( Subtotal = $1,487,455 ) |
| | 2014 | 2014 | INTERNATIONAL AIDS VACCINE INITIATIVE | 110 WILLIAM STREET | NEW YORK | NY | 10038 | NEW YORK | USA | U19AI090970 | Interplay of B cells and HIV Leading to Broad Neutralizing Antibody Responses | 000 | 5 | NIH | 7/31/2014 | $1,487,455 |
|
| Issue Date FY: 2013 ( Subtotal = $2,760,465 ) (Continued on the next page) |
| | 2013 | 2013 | INTERNATIONAL AIDS VACCINE INITIATIVE | 110 WILLIAM STREET | NEW YORK | NY | 10038 | NEW YORK | USA | U19AI090970 | Interplay of B cells and HIV Leading to Broad Neutralizing Antibody Responses | 001 | 4 | NIH | 8/26/2013 | $877,143 |
| | 2013 | 2013 | INTERNATIONAL AIDS VACCINE INITIATIVE | 110 WILLIAM STREET | NEW YORK | NY | 10038 | NEW YORK | USA | R01AI084840 | USING VSV VECTORS TO DISPLAY AND EVOLVE NOVEL HIV ENVELOPE IMMUNOGENS | 000 | 5 | NIH | 7/18/2013 | $477,940 |
| | 2013 | 2013 | INTERNATIONAL AIDS VACCINE INITIATIVE | 110 WILLIAM STREET | NEW YORK | NY | 10038 | NEW YORK | USA | U19AI090970 | Interplay of B cells and HIV Leading to Broad Neutralizing Antibody Responses | 000 | 4 | NIH | 8/14/2013 | $1,405,382 |
|
